
Pharmacally
PH-HFpEF
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in PH-HFpEF
Health TidingsTNX-103 Posts Strong Subgroup Results in PH-HFpEF Despite LEVEL Trial MissTenax’s TNX-103 improved 6-minute walk distance by 26.3 meters in a lower-functioning PH-HFpEF subgroup after the overall LEVEL trial missed its primary endpoint.Fact-Checked
Clinical TrialsTNX-103 Misses Primary Endpoint, Shows Benefit in More Severe PH-HFpEFTenax Therapeutics’ TNX-103 failed to significantly improve 6-minute walk distance in the Phase 3 LEVEL trial in PH-HFpEF, but prespecified analyses showed a 26.3-meter benefit in patients with…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.